title: [Therapy of normal tension glaucoma: effect of brinzolamide on ocular haemodynamics].
abstract: BACKGROUND
  Altered ocular perfusion plays a role in the pathophysiology of normal tension glaucoma. Dorzolamide, a locally applied inhibitor of carbonic anhydrase, is thought to increase ocular blood flow. Less data are available regarding the influence exercised on ocular perfusion by brinzolamide, another and different, locally administered, inhibitor of carbonic anhydrase.
  
  
  METHODS
  n = 15 eyes of 8 normal tension glaucoma patients were subjected to colour Doppler imaging and Langham-OBF (LOBF) before and during a therapy for 3 - 5 weeks with brinzolamide.
  
  
  RESULTS
  Brinzolamide reduces intraocular pressure from 15.8 +/- 0.9 to 12.6 +/- 0.9 mm Hg (n = 15; P < 0.05). Systolic as well as diastolic blood flow velocities, resistive (RI) and pulsatility index (PI), measured by CDI, remained unchanged in the presence of brinzolamide. LOBF values are also not influenced by brinzolamide (1014 + 115 before vs. 1113 +/- 178 microl under therapy; n = 15; n. s.).
  
  
  CONCLUSIONS
  Brinzolamide does not exercise any impact on ocular haemodynamics. This is different from the properties of dorzolamide that had been reported previously.
authors.affiliation: Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Augenheilkunde, Hamburg.
authors.forename: Maren
authors.initials: M
authors.lastname: Klemm
authors.forename: Oliver
authors.initials: O
authors.lastname: Zeitz
authors.forename: Juliane
authors.initials: J
authors.lastname: Reuss
authors.forename: Eike T
authors.initials: ET
authors.lastname: Matthiessen
authors.forename: Gisbert
authors.initials: G
authors.lastname: Richard
mesh_terms: D001783:Blood Flow Velocity / Q000187:drug effects; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005123:Eye / Q000098:blood supply*; D005901:Glaucoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009883:Ophthalmic Solutions; D011673:Pulsatile Flow; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013843:Thiazines / Q000009:adverse effects* / Q000627:therapeutic use; D018615:Ultrasonography, Doppler, Color; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013843:Thiazines; C111827:brinzolamide